Denali Therapeutics

Develops treatments for neurodegenerative diseases

South San Francisco, California, United States

About Denali Therapeutics

Denali Therapeutics focuses on finding and developing treatments for neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS, which involve the gradual loss of nerve cells and can lead to serious physical and mental challenges. The company uses scientific research to understand the biological pathways that lead to these diseases, aiming to create drugs that target specific molecules in the body to treat them. Denali stands out from its competitors by combining its own research efforts with partnerships with other biotech firms and pharmaceutical companies, allowing it to share risks and access new technologies. The goal of Denali Therapeutics is to create effective treatments that improve the lives of patients suffering from these debilitating conditions.

South San Francisco, CaliforniaHeadquarters
2015Year Founded
$337.5MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Risks

Failure in ALS trials raises concerns about pipeline efficacy.
Increased competition in ALS treatment could impact market share.
Discontinuation of programs due to toxicities highlights potential development challenges.

Differentiation

Denali focuses on neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS.
The company employs a science-driven approach to translational medicine and clinical development.
Denali leverages partnerships to access new technologies and spread financial risk.

Upsides

Denali's $500 million financing strengthens its financial position for pipeline advancement.
Partnership with Biogen could accelerate Parkinson's treatment development.
Focus on blood-brain barrier technology shows promise in treating lysosomal storage diseases.

Funding

Total raised$337.54 M
Latest valuation$650.00 M
StageIPO
POST IPO EQUITY
1/31/2024
$500
IPO
11/30/2017
$250
SERIES B
7/31/2016
$130
$650.00 M